|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1990-7-20
|
|
pubmed:abstractText |
Despite a success rate of more than 90 percent in inducing remission in children with acute lymphocytic leukemia, 30 to 40 percent of such children relapse. Maintenance therapy during remission usually includes oral mercaptopurine and methotrexate. Recently, wide variability in the bioavailability of oral mercaptopurine has been demonstrated, and there is concern that this may affect the risk of relapse.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0028-4793
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
5
|
|
pubmed:volume |
323
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
17-21
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:2355954-6-Mercaptopurine,
pubmed-meshheading:2355954-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2355954-Biological Availability,
pubmed-meshheading:2355954-Child,
pubmed-meshheading:2355954-Child, Preschool,
pubmed-meshheading:2355954-Dose-Response Relationship, Drug,
pubmed-meshheading:2355954-Humans,
pubmed-meshheading:2355954-Methotrexate,
pubmed-meshheading:2355954-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:2355954-Prognosis,
pubmed-meshheading:2355954-Prospective Studies,
pubmed-meshheading:2355954-Recurrence,
pubmed-meshheading:2355954-Remission Induction,
pubmed-meshheading:2355954-Risk Factors,
pubmed-meshheading:2355954-Survival Analysis,
pubmed-meshheading:2355954-Xanthine Oxidase
|
|
pubmed:year |
1990
|
|
pubmed:articleTitle |
Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children.
|
|
pubmed:affiliation |
Division of Clinical Pharmacology, Hospital for Sick Children, Toronto, ON, Canada.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
